An increase in cell surface PD-L1 upon TH1902 treatment of B16-F10 melanoma cells, in part potentially facilitated through TNFα-mediated autocrine regulation, provides the molecular rationale for combining TH1902 and anti-PD-L1 CPI strategies in order to bypass resistance mechanisms. Here, TNF is linked to melanoma.